AUPH Q3 2021 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+50475.9% YoY

Gross Profit

$14M98.3% margin

Operating Income

-$50M-343.3% margin

Net Income

-$50M-342.6% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+121.6%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$360M

Total Liabilities

$62M

Stockholders' Equity

$298M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$29,000	+50475.9%
Gross Profit	$14M	$29,000	+49600.0%
Operating Income	-$50M	-$42M	-19.0%
Net Income	-$50M	-$42M	-19.3%

Revenue Segments

Product

$15M100%

License

$29,0000%